Skip to main content

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK

Ward, Anthony, Caro, J.J., Getsios, D., Ishak, K., O'Brien, John T., Bullock, Roger A. (2003) Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. International Journal of Geriatric Psychiatry, 18 (8). pp. 740-747. ISSN 0885-6230. (doi:10.1002/gps.919) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:12305)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.
Official URL
http://dx.doi.org/10.1002/gps.919

Abstract

Objective To assess the long-term health and economic impact of treating mild to moderate Alzheimer's disease (AD) with galantamine (16 mg or 24 mg per day) compared to no cholinesterase therapy in the UK

Item Type: Article
DOI/Identification number: 10.1002/gps.919
Additional information: IN FILE
Subjects: R Medicine > RC Internal medicine > RC321 Neuroscience. Biological psychiatry. Neuropsychiatry
Divisions: Divisions > Division for the Study of Law, Society and Social Justice > School of Social Policy, Sociology and Social Research
Depositing User: M.P. Stone
Date Deposited: 12 Sep 2008 13:45 UTC
Last Modified: 16 Nov 2021 09:50 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/12305 (The current URI for this page, for reference purposes)
  • Depositors only (login required):